HealthMore in Health→
Zodasiran Posts Early Trial Gains in Triglycerides and LDL-Linked Risk Markers
Key Takeaways
- Phase 1 data showed no serious treatment-related adverse events.
- All study cohorts reported major ANGPTL3 and triglyceride reductions by week 16.
- The findings support larger studies across multiple dyslipidemia types.
DE
DT Editorial Team··via nature.com